

## EDITOR-IN-CHIEF

**Laura L. Kiessling**  
University of Wisconsin, Madison

## BOARD OF EDITORS

**Jennifer A. Doudna**  
University of California, Berkeley

**Kai Johnsson**  
Ecole Polytechnique Fédérale de Lausanne

**Anna K. Mapp**  
University of Michigan, Ann Arbor

**Michael A. Marletta**  
University of California, Berkeley

**Peter H. Seeberger**  
Eidgenössische Technische Hochschule

**James R. Williamson**  
The Scripps Research Institute

## EDITORIAL ADVISORY BOARD

**Carolyn R. Bertozzi**  
University of California, Berkeley

**Brian T. Chait**  
Rockefeller University

**Tim Clackson**  
ARIAD Pharmaceuticals, Inc.

**Jon C. Clardy**  
Harvard Medical School

**Benjamin F. Cravatt**  
The Scripps Research Institute

**Peter B. Dervan**  
California Institute of Technology

**Rebecca W. Heald**  
University of California, Berkeley

**Linda C. Hsieh-Wilson**  
California Institute of Technology

**Tony Hunter**  
Salk Institute

**Stephen C. Kowalczykowski**  
University of California, Davis

**Richard H. Kramer**  
University of California, Berkeley

**Thomas V. O'Halloran**  
Northwestern University

**Hiroyuki Osada**  
RIKEN

**Anna M. Pyle**  
Yale University

**Ronald T. Raines**  
University of Wisconsin, Madison

**Charles Sawyers**  
University of California, Los Angeles

**Stuart L. Schreiber**  
Harvard University

**Peter G. Schultz**  
The Scripps Research Institute

**Michael P. Sheetz**  
Columbia University

**H. Ulrich Stilz**  
Sanofi-Aventis, Frankfurt

**Christopher T. Walsh**  
Harvard Medical School


## When in Doubt, Ask!

One of the most perplexing questions that scientists using nontraditional approaches face is where to publish their research. This question is equally challenging for scientists using established procedures to obtain results that have multidisciplinary implications. In a high-stakes environment where so much depends on the rapid dissemination of results, scientists benefit from determining the suitability of their research for a particular audience prior to manuscript submission. At *ACS Chemical Biology* (ACSCB), we encourage potential authors to contact us if they need additional information on the suitability of their work for our journal.

The field of chemical biology is widely regarded as having evolved from the use of chemical approaches to solving biological problems. In the past few years, this field has expanded from its original roots and now spans many traditional disciplines. This rapid growth has had many effects, one of which is that many scientists now describe themselves as chemical biologists. However, we often speak with scientists working at the interface of biology and chemistry who do not necessarily define themselves as chemical biologists. We are asked by these scientists whether ACSCB would consider research appealing to a broad readership of chemists and biologists. The answer is a resounding "Yes!" At ACSCB, we feel that considering oneself a chemical biologist is not a prerequisite for publishing research of interest to the community.

This last point is particularly worth emphasizing. In the inaugural issue of ACSCB, our Editor-in-Chief Laura Kiessling spelled out that the vision for the journal would include responding to new scientific directions and serving the interests of the broader scientific community (1). We continue to strive toward this goal. For instance, in this issue of ACSCB, we present topics that a biophysicist, pharmacologist, or molecular biologist might find interesting. We include an analysis of the physical properties of lipids in cell membranes (2), two studies that suggest new ways to target key proteins that might help design next-generation drugs for certain cancers (3, 4), and a concise review of how state-of-the-art technologies in molecular electron microscopy enable scientists to view subcellular structures (5). Although our diverse topics might not always fit a traditional definition of chemical biology, we are confident that those interested in chemistry and biology will find our content appealing.

Going back to the dilemma of where to publish: if you have results that you would like to submit for publication in ACSCB, but you are not sure of the appropriateness for our audience, please inquire. You may send us a short summary of your work, and we will respond rapidly and indicate our level of interest in receiving a complete manuscript. When it comes to publishing your results, we'd like to help you make the right decision.



Anirban Mahapatra  
Assistant Managing Editor, *ACS Chemical Biology*

## REFERENCES

1. Kiessling, L. (2006) Fostering major breakthroughs, *ACS Chem. Biol.* 1, 1–2.
2. Veatch, S., Cicuta, P., Sengupta, P., Honerkamp-Smith, A., Holowka, D., and Baird, B. (2008) Critical fluctuations in plasma membrane vesicles, *ACS Chem. Biol.* 3, 287–293.
3. Xie, P., Williams, D., Atilla-Gokcumen, G., Milk, L., Xiao, M., Smalley, K., Hertyn, M., Meggers, E., and Marmorstein, R. (2008) Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity, *ACS Chem. Biol.* 3, 305–316.
4. Gunther, J., Moore, T., Collins, M., and Katzenellenbogen, J. (2008) Amphipathic benzenes are designed inhibitors of the estrogen receptor  $\alpha$ /steroid receptor coactivator interaction, *ACS Chem. Biol.* 3, 282–286.
5. Stahlberg, H., and Walz, T. (2008) Molecular electron microscopy: state of the art and current challenges, *ACS Chem. Biol.* 3, 268–281.